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Abstract 
The liver-specific toxin microcystin-LR (MC-LR) is a potent inhibitor of type 1 (PPl) and type 2A (PP2A) protein phosphatases. A tritiated form 
of the toxin, [‘Hldihydromicrocystin-LR ([‘HIDMC-LR). was used to identify target proteins in cellular fractions prepared from rat liver homogenates. 
About 80% of the [3H]DMC-LR bound to proteins was in the cytosolic fraction, which contained essentially all of the PPZA. In contrast, much of 
the PPl was found in particulate fractions, each with only a few percent of the total protein-bound [3]HDMC-LR. Protein-bound [3H]DMC-LR in 
the cytosol co-eluted with PPZA, but not with PP-1 from a DEAE-Sepharose column. Native forms of liver cytoplasmic PPZA and PPl separated 
by aminohexyl-Sepharose adsorption showed similar sensitivity to inhibition by MC-LR, and bound [3H]DMC-LR proportional to the amount of 
phosphatase activity. The results indicate that [3H]DMC-LR can bind both PP2A and PPl in the liver which must be important for microcystin- 
induced toxicity, but is recovered mainly bound to PPZA in the cytosol. 




Microcystins are potent liver toxins produced by dif- 
ferent species of cyanobacteria (blue-green algae), which 
can form blooms in lakes and water reservoirs [ 11. These 
toxins are cyclic heptapeptides and microcystin-LR 
(MC-LR), which is one of the more frequently studied 
forms of these peptides, has the basic structure cyclo(-D- 
Ala-L-X-erythro-cl-methyl-Asp-L-Y -ADDA-D-Glu-N- 
methyldehydro-Ala) where X and Y denote variable L- 
amino acid residues [2-4] and ADDA is an abbreviation 
for the a-amino acid, 3-amino-9-methoxy-2,6,8- 
trimethyl-phenyldeca-4,6-dienoic acid [2]. 
The primary target organ for microcystins is the liver 
[5,6], where the toxins cause complete disruption of the 
liver architecture, leading to rapid death of the animal 
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(the LD,, in mouse (i.p.) is 50 &kg) [7,8]. At the cellular 
level microcystins induce severe morphological changes 
and a total reorganization of the microfilaments [9]. The 
cellular specificity and organotropism of microcystins 
[5,10] is due to a selective transport system present only 
in hepatocytes, namely the multi-specific bile acid trans- 
port system [l 11. 
In isolated hepatocytes microcystins induce an overall 
increase in phosphorylation of cytosolic and cytoskeletal 
proteins [12] and it has been shown in vitro that micro- 
cystins are potent inhibitors of the protein phosphatases 
1 and 2A (PPl and PP2A) [12-161. PPl and PP2A are the 
most abundant phosphatases in mammalian tissues with 
catalytic subunits of 38 and 36 kDa, respectively [17]. 
These phosphatases dephosphorylate serine/threonine 
residues on a great variety of regulatory and structural 
proteins [ 181. MC-LR inhibits the purified catalytic sub- 
units of PPl and PP2A with approximately equal po- 
tency (range of reported ICw values: PPl 0.06-6 nM; 
PP2A 0.01-2 nM, [12-161, which gives this com- 
pound inhibitory properties similar to those of calyculin 
A [ 191. Whereas MC-LR and calyculin A inhibit PP2A 
with similar potency as okadaic acid, they are 50- to 
lOO-fold more effective than okadaic acid as PPl inhib- 
itors [19,20]. Immobilized MC-LR has been used to af- 
finity purify PP2A [21]. However, the binding capacity 
(3 ,ug PP2A/l mg MC-LR) was only 0.03% of that ex- 
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petted, probably because coupling to the matrix involved 
one of the MC-LR carboxyl groups that is important for 
binding to PP2A [22]. 
Some attempts have been made to identify the subcel- 
lular binding target for MC-LR. These studies have re- 
vealed that when whole liver is perfused, or hepatocytes 
in suspension are incubated, with [3H]DMC-LR, the ra- 
dioactivity is mainly found in the cytosolic fractions [23]. 
It has been shown that radiolabelled MC-LR in liver 
cytosol binds to a monomeric protein with a molecular 
weight of 40 kDa [24]. Whereas PP2A is known to be 
predominantly cytosolic, much of PPl is located in par- 
ticulate fractions. The present study was performed in 
order to determine whether PPl and/or PP2A are the 
proteins that bind [3H]DMC-LR in liver homogenates. 
2. Materials and methods 
2.1. Toxin and chemicals 
MC-LR was isolated and purified from toxic blooms of the cyano- 
bacterium Microcystis aeruginosa, and the pure toxin was tritiated to 
yield ‘H-labelled dihydromicrocystin-LR ([‘HIDMC-LR; specific activ- 
ity 170 mCi/mmol; 142 mCi/mmol by gel filtration binding assay) as 
described elsewhere [5]. The identity of the labelled compound was 
confirmed by fast atomic bombardment mass spectrometry (Toivola, 
D., Poon, G. and Eriksson, J., unpublished results). All salts and or- 
ganic compounds were of reagent grade and purchased from Sigma 
Chemicals Co. (St. Louis, MO, USA) or Merck (Darmstadt, Germany). 
2.2. Liver homogenization, [‘H]DMC-LR treatment and subcellular 
fractionation of homogenates 
Sprague-Dawley rats were anaesthetized (Nembutal, i.p.), the liver 
was rapidly removed, rinsed in wash buffer (50 mM imidazole, pH 7.4, 
150 mM NaCl) and minced in homogenization buffer (50 mM imi- 
dazole, pH 7.4, 5 mM EDTA, 5 mM EGTA, 250 mM sucrose, 50 mM 
2-mercaptoethanol), supplemented with the protease inhibitors phen- 
ylmethylsulfonyl fluoride (5 mM) and benzamidine (5 mM). The liver 
was homogenized and 5 ~1 of [‘H]DMC-LR in methanol was added to 
the crude homogenate (5 &30 ml homogenate equivalent to 0.17 ,uM, 
100 times the I& for PPl and PP2A). The homogenate was centrifuged 
to pellet the nuclear and cytoskeletal fraction (1,000 x g, 10 min), the 
mitochondria, lysosomes and peroxisomes (10,000 x g, 30 min) and the 
microsomal and plasma membrane fraction (100,000 x g, 60min). The 
final supernatant (100,000 x g) contains the cytosol. Pellets were dis- 
solved in homogenization buffer and aliquots of every fraction were 
then diluted in 2 x sample buffer (0.1 M Tris-HCl, pH 6.8, 2% SDS, 
20% glycine, 0.01% Bromphenol blue, 0.3% 2mercaptoethanol and 
6 M urea). Samples were separated by polyacrylamide gel electrophore- 
sis (PAGE) and analyzed for PP2A and PPl by Western blotting as 
described below. The experiments were repeated with livers from 3 
different animals with similar results. 
2.3. Determination of bound [‘H]DMC-LR in subcellular fractions 
Samples of each subcellular fraction were treated with 1% Triton 
X-100 (to solubilize membranes) and the proteins were then precipi- 
tated by addition of TCA to a final concentration of 10%. This proce- 
dure separated protein-bound [3H]DMC-LR from excess unbound 
[‘HIDMC-LR in each subcellular fraction. The radioactivity in the 
protein pellet after centrifugation was regarded as [‘H]DMC-LR bound 
to proteins, whereas the radioactivity in the TCA supernatant was 
considered to be unbound [‘H]DMC-LR, which does not precipitate in 
10% TCA. 
2.4. Identification of the (‘HJDMC-LR binding proteins in liver cytosol 
Because approximately 80% of [‘HIDMC-LR bound to proteins was 
found in the cytosol after subcellular fractionation, the cytosol was 
fractionated by DEAE-Sepharose CL-6B (Pharmacia) and Bio-Gel 
A-OSm (Bio-Rad) column chromatography. These methods did not 
involve denaturation of the proteins, as did acid precipitation, and 
afforded observations of MC-LR effects 100 times over the IC,, for PPl 
or PP2A. The chromatography buffer used was 50 mM imidazole, pH 
7.4, 5 mM EDTA, 5 mM EGTA, 10% glycerol and 50 mM 2-mercap- 
toethanol. A sample was applied to the 18ml DEAE and eluted with 
a salt gradient from 0 to 0.5 M NaCl (total volume 300 ml). The flow 
rate was 32 ml/h and the fractions eluted were collected every 10 min. 
The cytosolic proteins were also separated according to size on a Bio- 
Gel A-0.5m column in the same buffer. Individual fractions from Bio- 
Gel chromatography were tested for protein phosphatase activity [25]. 
2.5. Gel electrophoresis and Western blotting 
Every two DEAE fractions and every four Bio-Gel fractions were 
pooled. Proteins in the pooled fractions were precipitated with 12% 
TCA plus 0.0125% deoxycholic acid (final concentrations, w/v). The 
proteins were pelleted and washed 3 times with -20°C acetone. Pellets 
were allowed to dry before they were dissolved in 2 x sample buffer. 
After separation on 12% polyacrylamide gels, proteins were electro- 
transferred to nitrocellulose membranes (Bio-Rad, Richmond, CA, 
USA). Sheep anti-PPl affinity-purified antibodies [26] and rabbit anti- 
PP2A peptide antibodies [27], were used to identify the proteins. Bind- 
ing of primary antibodies to the membranes was detected by using 
alkaline phosphatase-conjugated secondary antibodies (Promega 
Corp., Madison, WI, USA, and Boehringer, Mannheim, Germany), or 
the ECL Western blotting detection system (Amersham, UK). Purified 
PPl and PP2A were used as positive controls. Low molecular weight 
standards from Pharmacia (Uppsala, Sweden) were used to calibrate 
protein size. Standards were stained with Ponceau S (0.5% Ponceau S. 
10% acetic acid). The relative intensity of Western Blot bands was 
measured by a densitometer. 
2.6. Further purification of PPI and PPZA 
Untreated rat liver homogenate was fractionated by centrifugation 
as described above, and the cytosol was applied to a 5 ml DEAE- 
column. The column was washed with the chromatography buffer and 
a fraction containing PPl and PP2A was eluted with 0.5 M NaCl (the 
elution and collection of the protein fraction was monitored with the 
Bradford protein assay). The fraction (3 ml) was further applied to a 
1 ml aminohexyl-Sepharose CL-6B column (AH-Sepharose) and PPI, 
which does not absorb well to AH-Sepharose, was eluted with 0.5 M 
NaCl (fraction 1). PP2A was eluted with 1.5 M NaCl in the same buffer 
(fraction 2). The two fractions were assayed for protein phosphatase 
activity with or without 2 nM okadaic acid to distinguish between PPl 
and PP2A. The PPase inhibition of a concentration series of MC-LR 
(0.1-5 nM) was also measured [25]. 
Cytosol from untreated homogenate was also run on a Bio-Gel A- 
0.5m column. Protein phosphatase activity was measured in every sec- 
ond fraction, as well as the inhibition of the PPase-activity, with 2 nM 
of okadaic acid. A unit of activity dephosphorylates 1 nmollmin of 10 
mM phosphorylase a at 30°C. The inhibition by MC-LR (0.1-5 nM) 
was measured on the fractions with ABC and AC forms of PP2A that 
were resolved by this chromatography. 
2.7. Gel-filtration binding assay 
The binding of [3H]DMC-LR to partially purified fractions of PPl 
and PP2A from AH-Sepharose (see above) was determined by a gel- 
filtration assay. 50 ~1 of each sample was incubated for 30 min with 
1,000 nM [‘H]DMC-LR at 22”C, and then applied to 300 ,ul of Se- 
phadex G-25 Fine. The samples were centrifuged briefly (l-2 s) at low 
speed through the Sephadex, and the flow through and another 50 ~1 
of buffer that was applied to the column were collected. The radioactiv- 
ity of each sample was measured. The DEAE flow through from the 
purification steps of fractions 1 and 2 was used as a negative control 
(data not shown). 
3. Results 
To identify binding proteins for MC-LR, [3H]DMC- 
LR was added to liver homogenates. The distribution of 
[3H]DMC-LR in subcellular fractions prepared by differ- 
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Fig. 1. Distribution of [‘H]DMC-LR in subcellular fractions of liver 
homogenates. Rat liver homogenates were treated with [3H]DMC-LR 
and subjected to subcellular fractionation as described in section 2. (a) 
The amount of protein-bound ‘H-MCLR in each fraction is expressed 
as the percentage of total protein-bound radioactivity. The total (100%) 
was determined as the sum of the individual subcellular fractions. Each 
bar represents the mean of 4 replicate experiments f SD. (b) Aliquots 
of the subcellular fractions were run on SDS-PAGE and Western blot- 
ted against PPZA and PPl as described in section 2. Lanes: A, 1,000 x g 
pellet; B, 10,000 x g pellet; C, 100,000 x g pellet; D, 100,000 x g (60 min) 
supernatant. Samples of purified PPl and PP2A were run as standards. 
Molecular weights are indicated at the right. 
ential centrifugation was determined using acid precipi- 
tation of proteins to separate toxin-protein complexes 
from toxin not bound to protein, which was soluble in 
10% TCA. The sum of the protein-bound [3H]DMC-LR 
of the individual fractions was taken as 100%. As shown 
in Fig. la, proteins that bound [3H]DMC-LR were pre- 
dominantly (78 & 2.0%) in the cytosolic fraction of the 
liver. Besides the cytosol, 13 f 2.3% of [3H]DMC-LR 
was found in the 1,000 x g pellet, and 4.3 ? 1.7%, and 
4.6 ? 1.9% was in the 10,000 x g and 100,000 x g pellets, 
respectively (Fig. la). Therefore, only a minor fraction 
of toxin bound to membrane or cytoskeletal proteins. 
Particulate samples treated with Triton X-100 prior to 
the precipitation, in order to better solubilize proteins, 
did not show any significant differences from samples 
not treated with Triton X-100 (data not shown). Distri- 
bution of PPl and PP2A in subcellular fractions was 
determined by Western immunoblotting. Nearly all of 
the PP2A was detected in the 100,000 x g supernatant as 
a 36 kDa protein (Fig. lb, lane D). In contrast, the 
catalytic subunit of PPl (38 kDa) was detected in the 
10,000 x g and 100,000 x g pellets (Fig. lb, lanes B and 
C) as well as in the 100,000 x g supernatant (Fig. lb, lane 
D). 
We analyzed the [‘HIDMC-LR protein complexes by 
chromatographic resolution and immunoblotting. Cy- 
tosol proteins eluted from a DEAE column showed one 
main peak with bound [3H]DMC-LR (Fig. 2a, centered 
at fraction 35) that eluted at about 250 mM NaCl. A 
peak of [3H]DMC-LR eluted in the flow through frac- 
tions (Fig. 2a, fractions l-14) but was determined to be 
free, rather than protein-bound toxin, based on its solu- 
bility in 10% TCA. Gel electrophoresis and immunoblot- 
ting of the proteins from DEAE fractions show that 
PP2A (36 kDa) was detected in fractions 3&41 (Fig. 2b), 
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Fig. 2. Binding of [rH]DMC-LR to cytosol proteins separated by ion- 
exchange chromatography. Cytosol (100,000 x g supernatant) from 
[3H]DMC-LR-treated liver homogenates was applied to a DEAE- 
Sepharose column, (a) The counts per minute (cpm) in 500 ~1 of every 
second eluted fraction (bars) and the relative intensity of PPZA (0) and 
PPI (A) immunoblotting (see section 2) are presented in relation to the 
salt gradient (- ~ -) and fraction number. (b) The proteins in the DEAE 
fractions were concentrated by acid precipitation, subjected to SDS- 
PAGE, and Western blotted against PP2A and PPI as described in 
section 2. Samples of purified PPZA and PPl were run as standards in 
the right-hand lanes. The molecular weights are indicated at the right. 
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filled circles). The PPl catalytic subunit was found as a 
38 kDa protein in fractions 24-33 (Fig. 2b) that eluted 
(Fig. 2a, filled triangles) just before PP2A. Co-elution of 
PP2A with [3H]DMC-LR suggests that a stable complex 
formed in rat liver cytosol. A complex between 
[3H]DMC-LR and PP-1 was not recovered after DEAE 
chromatography. 
Alternatively, [3H]DMC-LR binding was also ana- 
lyzed by gel filtration chromatography. The protein- 
bound peak of [3H]DMC-LR was eluted at an apparent 
molecular weight of greater than 100 kDa from Bio-Gel 
A-0.5m (not shown). Immunoblotting detected PP2A in 
fractions exactly coinciding with the elution of the peak 
of protein-bound [3H]DMC-LR. PPl was eluted in frac- 
tions at the leading edge of the peak of [3H]DMC-LR 
(not shown). 
These results showed co-elution of PP2A and protein- 
bound [3H]DMC-LR. However, both PPl and PP2A pu- 
rified catalytic subunits are known to be inhibited by 
MC-LR. To examine the binding and inhibition of the 
liver cytosolic forms of these phosphatases by MC-LR, 
they were further purified. The rat liver cytosol contain- 
ing PPl and PPZA was purified on DEAE-Sepharose 
CL6B, and further purified on AH-Sepharose to sepa- 
rate PPl (fraction 1) and PP2A (fraction 2). As expected 
from the subcellular distribution (Fig. l), the amount of 
PP2A was much higher than the amount of PPl in rat 
liver cytosol, evidenced by the 5-fold higher recovery of 
protein phosphatase activity (Table 1). The identity of 
the phosphatases in fractions 1 and 2 as PPl and PP2A, 
respectively, was confirmed by their different sensitivity 
to inhibition by 2 nM okadaic acid (Table 1). Both frac- 
tions 1 and 2 from AH-Sepharose bound radiolabelled 
toxin in a gel-filtration binding assay, and the amount of 
[3H]DMC-LR bound was proportional to the phos- 
phorylase phosphatase acitivity (Table 1). Based on the 
specific radioactivity of [3H]DMC-LR and assuming a 
specific activity of 1,000 nmol/min/mg for PP2A (using 
phosphorylase a as substrate) the binding corresponds to 
1 mol [3H]DMC-LR per mol of PP2A. 
Furthermore, the PPl in fraction 1 and PP2A in frac- 
tion 2 both showed dose-dependent inhibition by MC- 
LR with IC,,‘s of 0.3 and 0.5 nM, respectively (Fig. 3). 
[3H]DMC-LR also inhibited both protein phosphatases 
at these concentrations, showing that the radiolabelled 
Table 1 
Properties of rat liver cytosolic phosphatases 
Fraction Phosphorylase Inhibition of [‘HIDMC- Ratio 
phosphatase Pase-activity LR bound [3H]DMC- 
(pmol/min) by2nM @pm) LRlPPase 
okadaic acid activity 
(%) 
1 60 < 15 570 9.5 (PPl) 
2 318 83 2985 9.4 (PPZA) 
100 
0 
-10.0 -9.5 -9.0 -8.5 -8.0 
[MC-LR], log M 
Fig. 3. Inhibition of phosphorylase phosphatase activity of PPl (frac- 
tion 1) and PP2A (fraction 2) purified from rat liver cytosol by DEAE 
and AH-Sepharose column chromatography using various concentra- 
tions of MC-LR. Fraction 1 (7); fraction 2 (0). 
toxin itself was a potent inhibitor. The ABC hetrotrimer 
and AC heterodimer forms of rat liver PP2A were sepa- 
rated by Bio-Gel A-0.5m chromatography and resolved 
from residual PPl by AH-Sepharose adsorption and elu- 
tion. Both forms of PP2A were inhibited by nanomolar 
concentrations of MC-LR; the ABC form was inhibited 
like the fraction 1 sample and the AC form like the 
fraction 2 sample (see Fig. 3). These results showed that 
liver cytosolic forms of both PPl and PP2A were po- 
tently inhibited by MC-LR. 
4. Discussion 
Previous studies have demonstrated that nanomolar 
concentrations of MC-LR inhibit the catalytic subunits 
of both PPl and PP2A in vitro [12-161. However, the 
properties of the purified catalytic subunits are known 
to be markedly different from those of the holoenzymes 
with respect to substrate reactivity and inhibitor sensitiv- 
ity [l&28-30]. Therefore we wanted to study the binding 
of MC-LR to native forms of protein phosphatases 
found in the liver. 
Approximately 80% of the radiolabelled MC-LR 
bound to proteins was detected in the cytosolic fraction. 
This agrees with previous studies [21,23] on the distribu- 
tion of [3H]DMC-LR in either perfused liver or isolated 
hepatocytes. Therefore it seems to make little difference 
if the MC-LR was added to liver homogenates or to 
intact cells. In agreement with previous reports [18], we 
detected PP2A primarily in the cytosolic fraction, 
whereas much of the PPl was in the mitochondrial and 
post-mitochondrial particulate fractions. Furthermore, 
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the binding assay of [3H]DMC-LR to PPl and PP2A 
partially purified from the cytosol clearly showed that 
there was much more PP2A than PPl in the cytosol of 
rat liver. The [3H]DMC-LR binding to PPl and PP2A 
was directly proportional to the abundance of the respec- 
tive enzymes in liver cytosol. 
Our results indicated that the toxin in the cytosolic 
fraction was associated mostly with PP2A. The DEAE 
chromatography showed recovery of a complex of 
[3H]DMC-LR with PP%A, but not with PPl. It was esti- 
mated that MC-LR formed a stoichiometric complex 
with PP2A in an equilibrium binding assay. However, 
[3H]DMC-LR inhibited both PP2A and PPl recovered 
from liver cytosol with equal potency. Co-crystalization 
of MC-LR with PPl has been reported [31], removing 
any questions about whether the toxin can complex with 
both PPl and PP2A. Therefore binding of [3H]DMC-LR 
to PP2A in a complex that was the only one recovered 
from the liver homogenate cytosol probably reflects a 
difference in the stability of the toxin-PP2A complex 
relative to the toxin-PP-1 complex. It is conceivable that 
a covalent link was formed between [3H]DMC-LR and 
PP2A, not PPl, forming a non-dissociable and a disso- 
ciable complex, respectively. An ester or an isopeptide 
bond with one of the two carboxyl sidechains in MC-LR 
could be possible crosslinks. 
Injection of MC-LR into mice or rats causes rapid 
dissociation of the liver cells with complete disruption of 
liver morphology [7,8,32]. These morphological effects 
correspond well with the marked cytoskeletal rearrange- 
ments observed in freshly isolated hepatocytes exposed 
to MC-LR [9,12]. The changes in cytoskeletal microfil- 
ament organization induced by MC-LR are correlated 
with increases in overall protein phosphorylation [12]. 
Furthermore, the phosphorylation state of the liver inter- 
mediate filaments, cytokeratin 8 and 18, is markedly 
altered upon treatment of liver cells with MC-LR [12,33- 
35]. Correspondingly, calyculin A has been shown to 
induce hyperphosphorylation of vimentin, the principal 
intermediate filament in BHK-21 fibroblasts [36,37]. Se- 
lective inhibition [36] or microinjection of PPl [38] has 
implicated PPl as the predominant phosphatase in the 
dephosphorylation of vimentin and myosin light chains. 
Thus, PPl has a major role in the maintenance of cy- 
toskeletal networks and apparently is inhibited during 
liver toxicity produced by MC-LR. Consistent with inhi- 
bition of PPl in vivo by MC-LR there are observations 
that the toxin induces rapid liver glycogenolysis [8,33] 
and increases glucose release from hepatocytes [12]. The 
results in the present study show that inhibition of PP2A 
is also involved in the effects of MC-LR. This may result 
in kinase activation, since it is known that the activity of 
kinases, such as MAP-kinases, is regulated by the activ- 
ity of PP2A [39]. In this regard, formation of a stable 
complex of MC-LR with PP2A could provide an expla- 
nation for promotion of liver tumors by MC-LR [4042]. 
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